-

SHAREHOLDER ALERT: Kaskela Law LLC Investigates Fairness of $9.60 Per Share Buyout Price for Pzena Investment Management, Inc. Shareholders (PZN) and Encourages Investors to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Pzena Investment Management, Inc. (NYSE: PZN) (“Pzena”) on behalf of the company’s investors.

On July 26, 2022, Pzena announced that it would be acquired at a price of $9.60 per share in cash. Following the closing of the proposed transaction, Pzena’s shareholders will be cashed out of their investment position, and the company’s shares will no longer be publicly traded. As recently as February 2022, shares of Pzena’s stock traded above $10.50 per share.

The investigation seeks to determine whether Pzena shareholders will be receiving sufficient monetary consideration for their shares, and whether Pzena’s officers and directors violated the securities laws and/or breached their fiduciary duties in agreeing to sell the Company at $9.60 per share.

Pzena shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email (skaskela@kaskelalaw.com / abell@kaskelalaw.com) or online at https://kaskelalaw.com/cases/pzena-investment-management/ , for additional information about this investigation and their legal rights and options.

Kaskela Law LLC represents investors in securities fraud, corporate governance, and merger & acquisition litigation, and has helped recover in excess of $150 million on behalf of victimized investors. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

This notice may constitute attorney advertising in certain jurisdictions.

Contacts

D. Seamus Kaskela, Esq.
skaskela@kaskelalaw.com
Adrienne Bell, Esq.
abell@kaskelalaw.com
KASKELA LAW LLC
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com

Kaskela Law LLC

NYSE:PZN

Release Versions

Contacts

D. Seamus Kaskela, Esq.
skaskela@kaskelalaw.com
Adrienne Bell, Esq.
abell@kaskelalaw.com
KASKELA LAW LLC
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com

More News From Kaskela Law LLC

Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company’s current shareholders. The investigation seeks to determine whether Amneal or the company’s officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions. Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional infor...

Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company’s long-term investors. Click here for additional information: https://kaskelalaw.com/case/dexcom-inc/ Recently a securities fraud complaint was filed against DexCom on behalf of investors who purchased shares of the company's stock between January 8, 2024 and September 17, 2025 (the “Wrongdoing Period”). According to the complaint, during th...

Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Fortrea Holdings Inc. (Nasdaq: FTRE) (“Fortrea”) on behalf of the company’s long-term investors. Click here for additional information: https://kaskelalaw.com/case/fortrea-holdings/ Recently a securities fraud complaint was filed against Fortrea on behalf of certain investors who purchased shares of the company’s stock between July 5, 2023 and February 28, 2025 (the “Wrongdoing Period”). Accor...
Back to Newsroom